Targeted drug shows promise for Gene-Driven lung cancers
NCT ID NCT04084717
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests the drug crizotinib (XALKORI) in people with advanced non-small cell lung cancer that has spread and carries a change in the ROS1 or MET gene. Participants take crizotinib by mouth twice daily. The study aims to see how well the drug shrinks tumors and delays cancer growth, while also tracking side effects and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
crizotinib (XALKORI)
What this could lead to
If successful, this could provide an effective treatment option for people with advanced lung cancer driven by ROS1 or MET gene changes.
What could go wrong
This is a small, early-phase study, so results may not apply to all patients. Crizotinib can cause side effects like nausea, vision problems, and liver issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 1Z5, Canada